Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

By /

Ipsen and GENFIT announced that the U.S. Food and Drug Administration has accepted the New Drug Application for investigational elafibranor.

Scroll to Top